Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 639 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relative Bioavailability Clear all

Conditions: Healthy Volunteers
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Deferitazole (disodium salt, granule), Deferitazole (disodium salt, tablet), Deferitazole (magnesium hydroxide salt); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Erythematous Rosacea
Interventions: 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Fedratinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: AZD5462; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Volunteer
Interventions: ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Participants
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: divalproex sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Tolvaptan; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: solifenacin succinate suspension, solifenacin succinate tablet; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Opioid Dependence
Interventions: Probuphine (buprenorphine implant), Sublingual Buprenorphine; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Hepatitis B
Interventions: Bepirovirsen; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Anaemia
Interventions: GSK1278863A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Safety, and Tolerability
Interventions: DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg; Combination Product · Drug
Lead sponsor: Aspeya Switzerland SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Advanced Solid Tumors
Interventions: linifanib; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy
Interventions: Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Zolpidem 10mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets, UNIRETIC® 15/25 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Healthy Volunteers
Interventions: BMS-986435; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

Relative Bioavailability Study for GSK1278863A

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions

Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions

Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants